ArticleCerebrovascular diseases extra2026
Pharyngeal Electrical Stimulation versus None for Post-Stroke Dysphagia: Rationale, Design, and Protocol for the Parallel Group Superiority Pharyngeal Electrical Stimulation for Acute Stroke Dysphagia Trial (PhEAST) (ISRCTN98886991).
Article in Cerebrovascular diseases extra, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute ischaemic stroke and primary intracerebral haemorrhage are complicated by oropharyngeal dysphagia in more than 50% of patients. Currently, there are no definitive treatments for post-stroke dysphagia (PSD). Pharyngeal electrical stimulation (PES) can drive long-term beneficial changes in the cortical control of swallowing with functionally relevant reorganisation of the swallowing cortex correlating with reduced dysphagia.
methodsThe pharyngeal electrical stimulation for acute stroke dysphagia trial (PhEAST) is an international prospective randomised open-label blinded-endpoint parallel-group phase 4 superiority effectiveness trial. A total of 638 patients with PSD and dependency on nasogastric tube feeding are being recruited within 2-31 days of ictus. Participants are recruited from the UK and Austria and randomised to 6 days of optimised PES (given for 10 min each day) vs. no PES on top of standard care. The primary outcome is the dysphagia severity rating scale, an assessment of swallowing impairment, measured locally on day 14 and centrally at day 90 by trained observers masked to treatment and analysed using repeated measures regression analysis. Secondary outcomes include: functional oral intake scale, feeding status scale, international dysphagia diet standardisation initiative scale, presence of a feeding tube, pneumonia, antibiotic use, health-related quality of life, dependency, disability, frailty, mood, cognition, global impact and health economics at days 14, 90, 180, and 365. Safety measures include death and serious adverse events.
conclusionPhEAST has recruited more than 574 participants from 45 hospitals in the UK and Austria; recruitment will be complete at the end of October 2026. The attached Supplement summarises the protocol and follows the EQUATOR SPIRIT guideline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.